The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | Novel therapies and pitfalls in MPNs
Abdulraheem Yacoub, MD, of the University of Kansas Medical Center, Kansas City, MO, outlines novel therapy approaches and pitfalls in the treatment of myeloproliferative neoplasms (MPNs). Dr Yacoub explores the use of JAK inhibitors for this indication as well as ongoing clinical trials investigating combination therapies for MPNs. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
